WAVE Life Sciences (WVE) Highlights Growth Strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- S&P 500 and Nasdaq slip as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
September 28, 2023 4:15 PM EDTPresented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Waves best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK
WVE-006 industrys first-ever RNA editing clinical candidate on track for dosing in RestorAATion clinical trial in 4Q 2023 and first human proof-of-mechanism data in 2024
Advancing multiple, wholly owned RNA editing targets using correction and upregulation approaches; leveraging proprietary deep-learning model to unlock additional targets across the edit-verse
Wave platform chemistry enabling extra-hepatic delivery in RNA... More
